Abstract Number: 938 • 2018 ACR/ARHP Annual Meeting
Dermal Lymphatic Dysfunction and Photosensitivity in the MRL/Lpr Lupus Model
Background/Purpose: Proper function of lymphatic vessels is needed to limit the magnitude and duration of tissue inflammation. Chronic inflammatory states such as obesity and psoriasis…Abstract Number: 1685 • 2018 ACR/ARHP Annual Meeting
IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease characterized by deregulation of cytokine production. IL2 is an anti-inflammatory cytokine in SLE, but its loss…Abstract Number: 2112 • 2018 ACR/ARHP Annual Meeting
IFN-Gene Expression Is Elevated in Subacute Cutaneous Lupus Erythematous and DLE and Decreases with Treatment in DLE
Background/Purpose: Patients with SLE have increased type I IFN-regulated gene expression in peripheral blood, which has been correlated with systemic disease activity. IFN-regulated gene expression…Abstract Number: 2684 • 2018 ACR/ARHP Annual Meeting
Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients
Background/Purpose: Type I interferon has been identified as one of the central mediators in the pathogenesis of SLE, such that patients are characterized by activation…Abstract Number: 475 • 2018 ACR/ARHP Annual Meeting
Adolescents’ Perspectives on Living with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Non-adherence to medical recommendations in childhood-onset systematic lupus erythematosus (cSLE) is estimated to be between 40-50%. For patients with cSLE, non-adherence results in increased…Abstract Number: 975 • 2018 ACR/ARHP Annual Meeting
Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study
Background/Purpose: Cardiovascular disease is a leading cause of death for patients with systemic lupus erythematosus (SLE), and the disease is widely known to feature premature…Abstract Number: 1699 • 2018 ACR/ARHP Annual Meeting
Autoantibodies to M-Phase Phosphoprotein I (MPP-1: KIF20B) in Systemic Lupus Erythematosus
Background/Purpose: M-phase phosphoprotein (MPP-1), also termed kinesin interacting protein (KIF20B), is a 210 kDa protein that is highly expressed during cell division. Autoantibodies to MPP-1…Abstract Number: 2120 • 2018 ACR/ARHP Annual Meeting
CD47- Signal Regulatory Protein Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus
CD47-Signal Regulatory Protein-Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus.Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease mediated by unbalanced activation of…Abstract Number: 2792 • 2018 ACR/ARHP Annual Meeting
The Effect of B Cell Targeted Therapies on Autoantibodies and Excessive Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a severe systemic autoimmune disease characterized by immune-complexes (ICx) which cause inflammation and damage. Effective targeting of autoantibody secreting…Abstract Number: 706 • 2018 ACR/ARHP Annual Meeting
Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Background/Purpose: Resistant hypertension (RHTN) is associated with increased risk of cardiovascular events in the general population. Patients with systemic lupus erythematous (SLE) have increased cardiovascular…Abstract Number: 1079 • 2018 ACR/ARHP Annual Meeting
Plasma Metabolomic Analysis Combined with Transcriptome Data Has Revealed the Importance of Amino Acids Homeostasis in SLE Pathogenesis
Background/Purpose: Recently, many reports on immune metabolism have been accumulated and metabolic changes are now considered to be a key factor for controlling immune cell…Abstract Number: 1855 • 2018 ACR/ARHP Annual Meeting
Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus
Background/Purpose: Activation of the alternative and terminal attack complex of the complement system has been associated with adverse pregnancy outcomes (APOs) in stable/quiescent systemic lupus…Abstract Number: 2123 • 2018 ACR/ARHP Annual Meeting
Analysis of Lupus Synovitis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated within Infiltrating Immune Cells
Background/Purpose: Arthritis is a common manifestation of SLE but the inflammatory and immune cells that infiltrate synovium and the signaling pathways activated are not well…Abstract Number: 2852 • 2018 ACR/ARHP Annual Meeting
Excessive Formation of Neutrophil Extracellular Traps: Different Role in the Pathogenesis of ANCA-Associated Vasculitis and Systemic Lupus Erythematosus
Background/Purpose: ANCA-associated vasculitis (AAV) and systemic lupus erythematosus (SLE) both cause glomerulonephritis with pauci-immune and full-house immunofluorescence patterns, respectively. Although AAV and SLE are clinically…Abstract Number: 712 • 2018 ACR/ARHP Annual Meeting
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Background/Purpose: Tuberculosis (TB) has complex interplay with systemic lupus erythematosus (SLE). In addition, SLE, corticosteroid, and immunosuppressants are associated with TB infection. However, the prognostic…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 38
- Next Page »